PSI-6130

Tags: Drug.

PSI-6130 is an experimental treatment for hepatitis C. PSI-6130 is a member of a class of antiviral drugs known as nucleoside polymerase inhibitors that was created by chemist Jeremy L. Clark. Specifically PSI-6130 inhibits the hepatitis C virus RNA dependant RNA polymerase called NS5B.PSI-6130 is currently being developed by Hoffmann–La Roche as a 3’5′-diisobutyrl ester prodrug R7128. R7128 is part of the combination of all-oral agents clinical trial known as INFORM-1.

thumbnail

ATC prefix

none

CAS number

817204-33-4

FDA UNII code

05J68784G1

IUPAC name

4-Amino-1-((2R3R4R5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one